Aortech in dispute with biggest customer
Shares in Aortech International, the developer of a polymer for medical devices, fell following the announcement that it is in dispute with its largest customer, St Jude Medical.
Shares in Aortech International, the developer of a polymer for medical devices, fell following the announcement that it is in dispute with its largest customer, St Jude Medical.
The dispute centres around the use that St Jude Medical is making of Optim, which is actually Elasteon supplied by Aortech. Aortech alleges that there has been a "material breach of contract" by St Jude Medical.
Chairman Bill Brown explained that the material is used to insulate pacemakers, but declined to explain the exact nature of the breach of contract.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
It is the latest blow in a long-running saga that has given investors a white knuckle ride over the past year, during which its share price hit a high of 371p before plummeting.
In late September, Aortech's shares halved after warning that takeover talks had collapsed and that it was investigating funding options.
CM
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
8 of the best houses for sale with annexes
The best houses with annexes – from a period property in the Lake District to a 13th-century house with a two-bedroom annexe in Saltwood, Kent
By Natasha Langan Published
-
Zelenskyy moves to appease Donald Trump – what happens now?
Ukraine’s president Volodymyr Zelenskyy is conceding ground to secure the least-worst deal possible, says Emily Hohler
By Emily Hohler Published